Albuterol
Albuterol sulfate (salbutamol)
Brand names:Ventolin HFA, ProAir HFA, Proventil HFA, AccuNeb
A short-acting selective beta-2 adrenergic agonist and the universal first-line bronchodilator for acute bronchospasm. Albuterol is in essentially every aid bag, IFAK with bronchodilator stocking, and emergency response kit. MDI (metered-dose inhaler) and nebulizer formulations available; nebulizer preferred for severe exacerbations and tactical/EMS use.
Pharmacology and Actions
Albuterol selectively activates beta-2 adrenergic receptors on bronchial smooth muscle, producing bronchodilation through cyclic AMP increases and intracellular calcium decreases. Also reduces inflammatory mediator release from mast cells. Selective for beta-2 over beta-1 receptors at therapeutic doses, but selectivity is dose-dependent - high doses produce beta-1 effects (tachycardia, tremor).
Indications
- Acute bronchospasm (asthma exacerbation, COPD exacerbation)
- Reversible airway obstruction
- Anaphylaxis with bronchospasm (adjunct to epinephrine)
- Exercise-induced bronchospasm prophylaxis
- Hyperkalemia adjunctive treatment (drives K+ intracellularly)
- Tactical EMS use for blast lung, smoke inhalation with bronchospasm, and chemical exposure with reactive airway
Absolute Contraindications
- Known hypersensitivity to albuterol or sulfites (some formulations)
Precautions and Side Effects
Common: tachycardia, tremor (skeletal muscle, particularly noticeable in hands), palpitations, anxiety/jitteriness. Hypokalemia at high doses (drives K+ intracellularly - same mechanism used therapeutically in hyperkalemia). Hyperglycemia at high doses. Cardiac: QT prolongation at very high doses; cardiac ischemia in patients with coronary disease at high doses. Paradoxical bronchospasm (rare, more common with MDI propellants). Drug interactions: additive cardiovascular effects with other sympathomimetics; beta-blockers reduce efficacy; concurrent MAOIs or TCAs can intensify cardiovascular effects; hypokalemia potentiated by loop diuretics. Half-life 3 to 6 hours. Pregnancy Category C (extensively used in pregnancy; benefit-risk favors treatment for symptomatic asthma). Compatible with lactation. Pediatric use approved from age 2; nebulized form usable in infants for bronchiolitis (though clinical benefit debated). Tolerance can develop with overuse - if albuterol need is increasing, the underlying disease is worsening and requires reassessment. Monitor heart rate, K+ in severe exacerbations, and clinical response.
Adult Dosing
Pediatric Dosing
MDI: 2 puffs every 4 to 6 hours as needed (with spacer for younger children). Nebulized: 0.15 mg/kg (minimum 1.25 mg, maximum 2.5 mg) in 3 mL NS every 20 minutes for 3 doses in acute exacerbation.
Pharmacokinetics
Peak Effect: Inhaled: 30 to 60 minutes. Bronchodilation begins within 5 to 15 minutes.
Duration: 4 to 6 hours.
Storage and Handling
Store at room temperature (15 to 25 degrees C). Do not freeze. Protect MDI canisters from extreme heat (the pressurized contents can rupture). Nebulizer vials are stable in standard EMS conditions. Check MDI canister dose counter; many discard their actuator before the canister is actually empty.
Reconstitution:
MDI: priming may be required after disuse (check labeling). Nebulizer vials are pre-mixed at 2.5 mg in 3 mL NS, ready to use; can dilute concentrated 0.5 percent solution (5 mg/mL) for adult dosing. For continuous nebulization: 15 mg in 250 mL NS at 1 mL/minute.
TCCC and TECC Role
Albuterol is in the TCCC and TECC formulary for management of bronchospasm in casualties. TCCC indications include reactive airway disease exacerbation, blast lung with bronchospasm, smoke inhalation with reactive airway component, and bronchospasm component of anaphylaxis (adjunct to epinephrine). MDI with spacer is the field-preferred format in space-constrained kits; nebulizer is preferred in role 2 and hospital settings. Mission impact at standard doses is minor - tremor and tachycardia are real but typically tolerable; severe exacerbations producing the need for high-dose albuterol indicate the patient is not operationally functional regardless of medication effect.
Albuterol is the universal bronchodilator and one of the most operationally important medications in any aid bag containing reactive airway management capability. The MDI with spacer is dramatically more effective than MDI alone for delivery to small airways - operators carrying inhalers should also carry a spacer. For severe acute bronchospasm in the field, the nebulized dose can be repeated every 20 minutes; continuous nebulization is appropriate for status asthmaticus in role 2 settings. Combine with ipratropium (Atrovent) for synergistic bronchodilation in severe COPD or asthma exacerbations. The tachycardia and tremor are dose-related and predictable; warn operators starting albuterol that these effects are expected and not dangerous.
Withholding albuterol from a tachycardic patient with severe bronchospasm. The tachycardia from bronchospasm-induced hypoxia is far more dangerous than tachycardia from albuterol; the correct action is treat the bronchospasm aggressively. Heart rates of 130 to 140 are expected during severe asthma exacerbations and should not prevent appropriate bronchodilator dosing. The other mistake is using oral albuterol for acute exacerbation - the inhaled route is dramatically more effective with less systemic effect. The third mistake is failing to use a spacer with MDI - most of the medication impacts the back of the throat without a spacer.
This drug profile is provided as educational reference material for trained medical providers. It is not medical advice, not a substitute for formal training, and not a substitute for current published guidelines or medical direction.
Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances are subject to additional handling, accountability, and documentation requirements per DEA and state law. Always verify dosing, indications, contraindications, and route of administration against current published guidelines and your local protocols before administration.
If this content is being viewed during a medical emergency, call 911 immediately and follow the direction of your local emergency dispatch and medical control. Do not use this reference as a substitute for emergency medical services.
Drug information evolves. Last reviewed dates and source citations are provided for each entry. Confirm currency against the cited source before clinical use.
Penn Tactical Solutions publishes this reference for educational purposes. PTS does not provide medical direction and does not assume responsibility for clinical decisions made in the field. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Educational reference for trained medical providers. Not medical advice. Not a substitute for formal training, current published guidelines, or medical direction. Drug administration is governed by your scope of practice, agency standing orders, medical director protocols, and applicable state and federal regulations. Controlled substances require additional storage, accountability, and documentation per DEA and state law.
In a medical emergency, call 911. This reference is not a substitute for emergency medical services.
Verify dosing, indications, and contraindications against current published guidelines and your local protocols before administration. Confirm content currency against the source citation. Penn Tactical Solutions does not provide medical direction. Clinical responsibility rests with the administering provider, their medical director, and their agency.
Albuterol
| IV/IO | Not standard. Subcutaneous epinephrine or IM terbutaline preferred for severe refractory bronchospasm requiring parenteral beta-agonist. (None) |
| IM | None standard. (None) |
| IN | None (None) |
| PO | 2 to 4 mg PO 3 to 4 times daily. Oral formulation rarely used in modern practice - inhaled is preferred for efficacy and reduced systemic effects. (30 minutes) |